Introduction We investigated relations between amyloid-β (Aβ) status, apolipoprotein E
(APOE) ε4, and cognition, with cerebrospinal fluid markers of neurogranin (Ng) …

Objective To test the hypothesis that cognitively unimpaired individuals with Alzheimer
disease (AD) neuropathology differ from individuals with AD dementia on biomarkers of …

Introduction The neuronal loss in Alzheimer disease (AD) has been described to affect grey
matter in the cerebral cortex. However, in the elderly, AD pathology is likely to occur together …

Objective Widespread implementation of cerebrospinal fluid (CSF) biomarkers of
Alzheimer's disease (AD) in clinical settings requires improved accuracy for diagnosis of …

Introduction Within-person trajectories of cerebrospinal fluid (CSF) biomarkers in
Alzheimer's disease (AD) are not well defined. Methods We included 467 subjects from the …

Introduction The biological pathways involved in the preclinical stage of the Alzheimer's
continuum are not well understood. Methods We used NeuroToolKit and Elecsys® …

Alzheimer's disease (AD) is characterized by substantial neurodegeneration, including both
cortical atrophy and loss of underlying white matter fiber tracts. Understanding longitudinal …

Potential biomarkers for Alzheimer's disease (AD) include amyloid β1–42 (Aβ1–42), t-Tau, p-
Tau181, neurofilament light chain (NFL), and neuroimaging biomarkers. Their combined use …

Introduction Four less well-studied but promising “emerging” cerebrospinal fluid (CSF)
biomarkers are elevated in late-onset Alzheimer disease (AD): neurogranin, synaptosomal …

Background Neuroinflammation has gained increasing attention as a potential contributing
factor in the onset and progression of Alzheimer's disease (AD). The objective of this study …